VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema
- 159 Downloads
To investigate the association between VEGF gene polymorphisms and the responses to treatment with intravitreal ranibizumab (IVR) in patients with diabetic macular edema (DME).
This prospective study, conducted at the Kutahya Dumlupinar University Faculty of Medicine, included 95 patients with DME that were treated with IVR and 32 patients without DME despite proliferative diabetic retinopathy (PDR). The participants were divided into three groups: DME with non-proliferative diabetic retinopathy, DME with PDR, and PDR without DME; patients with DME who were treated with IVR were further divided into two groups based on their response to the treatment. Each patient was genotyped for five single nucleotide variations (SNVs) in VEGF-A: rs2010963, rs2146323, rs10434, rs833069, and rs6921438.
There was a statistically significant difference in allelic distribution of VEGF-A rs833069 polymorphism in relation to the severity of diabetic retinopathy (DRP) (p = 0.031). The allelic distribution of VEGF-A rs2146323 polymorphism tended to be associated with the severity of DRP (p = 0.069). There were no statistically significant differences in the allelic distribution of the studied five SNVs in DME patients regarding the patients’ responses to IVR therapy.
There is no association between the studied VEGF-A SNVs and the responses to IVR therapy in DME. However, the VEGF-A rs833069 gene polymorphism has a clear association with the severity of diabetic retinopathy.
KeywordsVEGF gene polymorphisms Diabetic macular edema Ranibizumab Diabetic retinopathy
This study was supported by the Dumlupinar University Scientific Research Projects Commission (Project Number: 2015–65).
Compliance with ethical standards
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
The study adhered to the tenets of the Declaration of Helsinki. The Institutional Review Board of the Dumlupinar University School of Medicine approved the study protocol.
Informed consent was obtained from all individual participants included in the study.
- 11.The Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:1064–1077CrossRefGoogle Scholar
- 12.The Diabetic Retinopathy Clinical Research Network, Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman S (2011) Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118:609–614CrossRefGoogle Scholar
- 13.Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, On behalf of the RIDE and RISE Research Group et al (2013) Long-term outcome of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trial: RIDE and RISE. Ophthalmology 120:2013–2022CrossRefGoogle Scholar